Related Experiment Videos
Absence seizures: valproate or ethosuximide?
Acta Neurologica Scandinavica. Supplementum
|January 1, 1983
Summary
Ethosuximide (ESM) and valproate (VPA) effectively treat absence seizures in children, with 80.8% achieving complete seizure reduction. VPA showed superiority in specific cases, and drug combinations are beneficial for refractory seizures.
Area of Science:
- Pediatric Neurology
- Epileptology
Background:
- Absence seizures are a common epilepsy syndrome in children.
- Treatment efficacy varies, necessitating evaluation of different antiepileptic drugs.
Purpose of the Study:
- To retrospectively analyze the treatment outcomes of absence seizures in children.
- To compare the effectiveness of ethosuximide (ESM) and valproate (VPA).
Main Methods:
- Retrospective analysis of 47 children with absence seizures.
- Evaluation of treatment with ESM and VPA, including combination therapy.
- Assessment of seizure frequency reduction and adverse events.
Main Results:
- 80.8% of children achieved 100% seizure reduction.
- ESM and VPA were effective as first-line treatments.
- Valproate (VPA) demonstrated superiority in treating absence seizures with EEG polyspikes or absence status.
Conclusions:
- Both ESM and VPA are essential for managing absence seizures in children.
- Combination therapy with ESM and VPA is beneficial for refractory cases.
- Valproate (VPA) is particularly effective for specific seizure types within absence epilepsy.